The best part of all of this patent discussion is the realization about how patents work - they are not the easiest thing to come by, there are often many rejections, and yet somehow people still get drug patents. Lovaza serves as a nice reminder that there are patent lawyers for a reason, and that what happens one day, or even multiple days, does not foretell the future.
Frankly, I hope Amarin does great as I am now a long holder, but I also hope that this story will help many investors gain an understanding of the journey of a drug. I urge you all to also look at the status of VVUS before it doubled in price - it's new blockbuster only had advisory board approval (after a previous rejection), and hasn't received FDA approval yet - still a price double because of its potential. There are a lot of positive indicators for 101, and I for one am quite interested to see what happens on this message board in July. Best of luck.
so this means we can expect another 4 or 5 patent rejections
or not ... i think it demonstrates the process and even final rejection doesn't mean what it implies to the layman... as investors in amrn we are on a journey with a bit of an unknown timetable... the frustration i experience is only when things don't happen according to MY amrn timetable :)